Cargando…
1080. OPAT at the End of Life?: Short- and Long-Term Mortality Following Outpatient Parenteral Antibiotic Therapy
BACKGROUND: Outpatient parenteral antimicrobial therapy (OPAT) patients have high rates of adverse drug events, emergency visits, and readmissions. Understanding correlates of mortality during and after OPAT may clarify opportunities to enhance care and meaningfully interpret the clinical profile of...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810866/ http://dx.doi.org/10.1093/ofid/ofz360.944 |
_version_ | 1783462342226345984 |
---|---|
author | Schranz, Asher J Kinlaw, Alan C Swartwood, Michael J Boerneke, Renae A Medlin, Tenesha Farel, Claire E |
author_facet | Schranz, Asher J Kinlaw, Alan C Swartwood, Michael J Boerneke, Renae A Medlin, Tenesha Farel, Claire E |
author_sort | Schranz, Asher J |
collection | PubMed |
description | BACKGROUND: Outpatient parenteral antimicrobial therapy (OPAT) patients have high rates of adverse drug events, emergency visits, and readmissions. Understanding correlates of mortality during and after OPAT may clarify opportunities to enhance care and meaningfully interpret the clinical profile of patients receiving OPAT. METHODS: We analyzed a cohort of patients enrolled in our OPAT program from 2015 to 2018. Patients were followed to death or December 31, 2018, whichever came first. Using Linkplus, we linked patients to North Carolina death records by name, birth date, and sex. We performed a probabilistic linkage and reviewed any nondeterministic matches. Clinical and demographic data were extracted by chart review. Cause of death was determined by first cause in the state death data, as indexed by ICD-10 code. Mortality rates were tabulated at 90 days and 1 year after treatment start. Predictors of 1-year mortality were assessed by multivariable logistic regression and adjusted for age, sex, Staphylococcus aureus infection, early antibiotic stop, and readmission. RESULTS: Among 729 OPAT courses in the study, the median age was 54 (interquartile range, IQR 44–65) and 60% were male. Seventy-seven deaths occurred during the period at a median 272 days (IQR 89–462), including 7 during OPAT (figure). Mortality at 90 days and 1 year was 3.1% (19 of 617 eligible OPAT courses) and 7.1% (31 of 408), respectively. 90-day mortality was equally due to infection (37%) and cancer (37%), whereas 1-year death was most commonly due to infection (32%). The most commonly reported causes of death at any time during the period were cancer (25%), infection (19%) and cardiovascular disease (17%). Each year increase in age was associated with a 5% relative increase in odds of 1-year death (odds ratio, OR, 1.05, 95% CI 1.02–1.08), and readmission was associated with risk of 1-year death (adjusted OR 7.78, CI 3.46–17.50). CONCLUSION: In this large OPAT cohort, 90-day mortality was 3% and 1-year mortality was 7%. Readmission during OPAT was a strong predictor of 1-year death. Strategies to decrease 1-year mortality may include mitigating readmissions or allocating resources after readmission. The prevalence of cancer-related death suggests an opportunity for OPAT providers and oncologists to collaborate in care of high-risk patients. [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6810866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68108662019-10-28 1080. OPAT at the End of Life?: Short- and Long-Term Mortality Following Outpatient Parenteral Antibiotic Therapy Schranz, Asher J Kinlaw, Alan C Swartwood, Michael J Boerneke, Renae A Medlin, Tenesha Farel, Claire E Open Forum Infect Dis Abstracts BACKGROUND: Outpatient parenteral antimicrobial therapy (OPAT) patients have high rates of adverse drug events, emergency visits, and readmissions. Understanding correlates of mortality during and after OPAT may clarify opportunities to enhance care and meaningfully interpret the clinical profile of patients receiving OPAT. METHODS: We analyzed a cohort of patients enrolled in our OPAT program from 2015 to 2018. Patients were followed to death or December 31, 2018, whichever came first. Using Linkplus, we linked patients to North Carolina death records by name, birth date, and sex. We performed a probabilistic linkage and reviewed any nondeterministic matches. Clinical and demographic data were extracted by chart review. Cause of death was determined by first cause in the state death data, as indexed by ICD-10 code. Mortality rates were tabulated at 90 days and 1 year after treatment start. Predictors of 1-year mortality were assessed by multivariable logistic regression and adjusted for age, sex, Staphylococcus aureus infection, early antibiotic stop, and readmission. RESULTS: Among 729 OPAT courses in the study, the median age was 54 (interquartile range, IQR 44–65) and 60% were male. Seventy-seven deaths occurred during the period at a median 272 days (IQR 89–462), including 7 during OPAT (figure). Mortality at 90 days and 1 year was 3.1% (19 of 617 eligible OPAT courses) and 7.1% (31 of 408), respectively. 90-day mortality was equally due to infection (37%) and cancer (37%), whereas 1-year death was most commonly due to infection (32%). The most commonly reported causes of death at any time during the period were cancer (25%), infection (19%) and cardiovascular disease (17%). Each year increase in age was associated with a 5% relative increase in odds of 1-year death (odds ratio, OR, 1.05, 95% CI 1.02–1.08), and readmission was associated with risk of 1-year death (adjusted OR 7.78, CI 3.46–17.50). CONCLUSION: In this large OPAT cohort, 90-day mortality was 3% and 1-year mortality was 7%. Readmission during OPAT was a strong predictor of 1-year death. Strategies to decrease 1-year mortality may include mitigating readmissions or allocating resources after readmission. The prevalence of cancer-related death suggests an opportunity for OPAT providers and oncologists to collaborate in care of high-risk patients. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810866/ http://dx.doi.org/10.1093/ofid/ofz360.944 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Schranz, Asher J Kinlaw, Alan C Swartwood, Michael J Boerneke, Renae A Medlin, Tenesha Farel, Claire E 1080. OPAT at the End of Life?: Short- and Long-Term Mortality Following Outpatient Parenteral Antibiotic Therapy |
title | 1080. OPAT at the End of Life?: Short- and Long-Term Mortality Following Outpatient Parenteral Antibiotic Therapy |
title_full | 1080. OPAT at the End of Life?: Short- and Long-Term Mortality Following Outpatient Parenteral Antibiotic Therapy |
title_fullStr | 1080. OPAT at the End of Life?: Short- and Long-Term Mortality Following Outpatient Parenteral Antibiotic Therapy |
title_full_unstemmed | 1080. OPAT at the End of Life?: Short- and Long-Term Mortality Following Outpatient Parenteral Antibiotic Therapy |
title_short | 1080. OPAT at the End of Life?: Short- and Long-Term Mortality Following Outpatient Parenteral Antibiotic Therapy |
title_sort | 1080. opat at the end of life?: short- and long-term mortality following outpatient parenteral antibiotic therapy |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810866/ http://dx.doi.org/10.1093/ofid/ofz360.944 |
work_keys_str_mv | AT schranzasherj 1080opatattheendoflifeshortandlongtermmortalityfollowingoutpatientparenteralantibiotictherapy AT kinlawalanc 1080opatattheendoflifeshortandlongtermmortalityfollowingoutpatientparenteralantibiotictherapy AT swartwoodmichaelj 1080opatattheendoflifeshortandlongtermmortalityfollowingoutpatientparenteralantibiotictherapy AT boernekerenaea 1080opatattheendoflifeshortandlongtermmortalityfollowingoutpatientparenteralantibiotictherapy AT medlintenesha 1080opatattheendoflifeshortandlongtermmortalityfollowingoutpatientparenteralantibiotictherapy AT farelclairee 1080opatattheendoflifeshortandlongtermmortalityfollowingoutpatientparenteralantibiotictherapy |